Pediatric demyelinating disease and anti ‐MOG antibody

The wide spectrum of MOG ‐associated CNS demyelination, including monophasic and relapsing forms, seems to be now better understood. Although most children have a good clinical outcome, MOGAD may be a severe relapsing and devastating disorder for a subgroup of patients. Considering the moderate response to current standar d relapse prevention therapies additional safe and long‐term efficacious treatment options are still much needed for children with relapsing MOG demyelination. AbstractSignificant progress has been made in the field of pediatric neuroimmunology over the past few years. With the detection of conformationally correct myelin oligodendrocyte glycoprotein (MOG) antibodies using cell ‐based assays, children with different monophasic and relapsing phenotypes have been increasingly described. However, there is still controversy regarding the severity of the disease course and outcome of this emerging and rapidly expanding spectrum of MOG‐associated demyelination. Accumulating evidence seems to identify MOG‐IgG–associated disorder as a disease entity different from multiple sclerosis and aquaporin 4 (AQP4)‐IgG–positive neuromyelitis optica spectrum disorder. This review will summarize recent findings regarding the spectrum of MOG‐associated disorders in pediatri c patients related to diagnosis, clinical presentation, and neuroimaging patterns, including data on current available and emerging treatment options for children.
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Tags: REVIEW ARTICLE Source Type: research